# Bimekizumab and Deucravacitinib: Mechanism of Action in Psoriasis Treatment

This article outlines the mechanisms of action for two psoriasis treatments: **Bimekizumab** and **Deucravacitinib**. 

Before we explore these novel therapies, it's important to note that psoriasis is particularly difficult to treat due to its complex interplay of genetic factors, environmental triggers, and immune system dysregulation. The disease manifests as chronic inflammation and hyperproliferation of keratinocytes, leading to thick, scaly skin plaques. Multiple immune pathways contribute to its pathogenesis, making it challenging to find effective treatments without significant side effects. Included is a treatment chart commonly referenced by dermatologists from UpToDate, highlighting current therapeutic approaches.

![Aprtxchrnplqpsorisadlt](https://github.com/user-attachments/assets/4556013b-cf22-4a79-b389-1e16fc4e9122)

## Bimekizumab

Bimekizumab is a monoclonal antibody designed to treat plaque psoriasis. Its mechanism of action includes:

1. Target: Bimekizumab selectively inhibits interleukin-17A (IL-17A) and interleukin-17F (IL-17F).
2. Primary effect: It blocks IL-17 signaling.
3. Downstream effects:
   - Reduces keratinocyte proliferation
   - Decreases neutrophil recruitment
   - Suppresses pro-inflammatory cytokine production
4. Cellular impact: Affects primarily keratinocytes and neutrophils.
5. Molecular pathway: Influences the NF-κB activation pathway.

----

![image](https://github.com/user-attachments/assets/359138f1-af68-4150-9bb2-2ac67a943069)

----

## Deucravacitinib

Deucravacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor used in the treatment of plaque psoriasis. Its mechanism of action includes:

1. Target: Deucravacitinib binds to the TYK2 enzyme's regulatory domain.
2. Primary effect: It inhibits TYK2-mediated signaling.
3. Downstream effects:
   - Reduces IL-23, IL-12, and Type I interferon signaling
   - Decreases Th17 and Th1 cell differentiation
   - Suppresses T cell activation
4. Cellular impact: Primarily affects T cells and dendritic cells.
5. Molecular pathway: Influences the JAK-STAT signaling pathway.

----

![image](https://github.com/user-attachments/assets/90f63a05-3bf8-4aaa-858c-1d866e30d8ca)

----

## Key Differences

1. Molecular target:
   - Bimekizumab: IL-17A and IL-17F cytokines
   - Deucravacitinib: TYK2 enzyme

2. Signaling pathways affected:
   - Bimekizumab: IL-17 signaling pathway
   - Deucravacitinib: IL-23, IL-12, and Type I interferon signaling pathways

3. Primary cellular effects:
   - Bimekizumab: Keratinocytes and neutrophils
   - Deucravacitinib: T cells and dendritic cells

4. Molecular pathways influenced:
   - Bimekizumab: NF-κB pathway
   - Deucravacitinib: JAK-STAT pathway
  
----

![image](https://github.com/user-attachments/assets/3957b662-97f1-4bb1-b811-afafd6b53a94)

----

Both medications are prescribed for the treatment of plaque psoriasis. The choice between them depends on various clinical factors and should be made under the guidance of a healthcare professional.
